Show simple item record

dc.contributor.authorCoker, EAen_US
dc.contributor.authorMitsopoulos, Cen_US
dc.contributor.authorTym, JEen_US
dc.contributor.authorKomianou, Aen_US
dc.contributor.authorKannas, Cen_US
dc.contributor.authorDi Micco, Pen_US
dc.contributor.authorVillasclaras Fernandez, Een_US
dc.contributor.authorOzer, Ben_US
dc.contributor.authorAntolin, AAen_US
dc.contributor.authorWorkman, Pen_US
dc.contributor.authorAl-Lazikani, Ben_US
dc.date.accessioned2019-01-24T16:12:51Z
dc.date.issued2019-01en_US
dc.identifier.citationNucleic acids research, 2019, 47 (D1), pp. D917 - D922en_US
dc.identifier.issn0305-1048en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3016
dc.identifier.eissn1362-4962en_US
dc.identifier.doi10.1093/nar/gky1129en_US
dc.description.abstractcanSAR (http://cansar.icr.ac.uk) is a public, freely available, integrative translational research and drug discovery knowlegebase. canSAR informs researchers to help solve key bottlenecks in cancer translation and drug discovery. It integrates genomic, protein, pharmacological, drug and chemical data with structural biology, protein networks and unique, comprehensive and orthogonal 'druggability' assessments. canSAR is widely used internationally by academia and industry. Here we describe major enhancements to canSAR including new and expanded data. We also describe the first components of canSARblack-an advanced, responsive, multi-device compatible redesign of canSAR with a question-led interface.en_US
dc.formatPrinten_US
dc.format.extentD917 - D922en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectProtein Interaction Mappingen_US
dc.subjectProtein Conformationen_US
dc.subjectUser-Computer Interfaceen_US
dc.subjectKnowledge Basesen_US
dc.subjectDrug Discoveryen_US
dc.subjectTranslational Medical Researchen_US
dc.subjectDatabases, Pharmaceuticalen_US
dc.titlecanSAR: update to the cancer translational research and drug discovery knowledgebase.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-11-26en_US
rioxxterms.versionofrecord10.1093/nar/gky1129en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2019-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNucleic acids researchen_US
pubs.issueD1en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.publication-statusPublisheden_US
pubs.volume47en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamComputational Biology and Chemogenomicsen_US
dc.contributor.icrauthorAl-Lazikani, Bissanen_US
dc.contributor.icrauthorMitsopoulos, Konstantinosen_US
dc.contributor.icrauthorWorkman, Paulen_US
dc.contributor.icrauthorAntolin Hernandez, Alberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/